Britain and America have announced a landmark trade agreement that will maintain no import taxes on British medicine exports entering the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to raise funding on drugs through the NHS. This move secures that duties on these key products will stay at nothing for a timeframe of 36 months.
This development follows previous warnings to hike import taxes on branded drug products, with potential rates discussed up to one hundred percent.
"This agreement between the UK bolsters the international landscape for cutting-edge drugs and brings much-needed equity to transatlantic medicine commerce," an announcement said.
Economic Importance
Drugs represent one of the UK's most significant export categories to the United States, which is by far the largest destination for leading companies like GSK and AstraZeneca.
Export figures reveal that in the 12 months leading up to September, the UK sold pharmaceutical products valued at £11.1bn to the US. This figure represented a significant portion of all goods exports in that timeframe.
"This agreement protects work, stimulates capital expenditure and facilitates the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary commented.
Key NHS Changes
The pact involves several key commitments from the United Kingdom:
- Price Threshold Increase: The UK will raise the affordability limit at which it considers new treatments to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to increase overall health service expenditure on medicines from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The amount pharmaceutical firms must pay back to the NHS to control costs will be limited at 15%. Previously, refunds topped twenty percent.
Industry Background
This agreement follows a long-running dispute between the sector and the UK government over spending levels and regulatory access.
This friction were heightened by arguments that American customers were charged significantly more for the identical medicines than consumers in the Britain and the EU.
In recent months, several large drug company projects in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been pledged toward American operations.
One official stated that the NHS had to increase expenditure on medicines, noting that its spending on drugs had declined as a proportion of its resources over the previous ten-year period.
